Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia

NCT04361032 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

260

Enrollment

OTHER

Sponsor class

Conditions

COVID19
Intensive Care Unit

Interventions

DRUG: Tocilizumab Injection
DRUG: Deferoxamine

Sponsor

Abderrahmane Mami Hospital

Collaborators

[object Object]
[object Object]